


AMENDMENTS TO THE SPECIFICATION:

Please amend the specification as follows:

Page 9, lines 12-23:

(6) A 2-acylaminothiazole derivative represented by the formula (III) or a pharmaceutically acceptable salt thereof.



[Symbols in the formula have the following meanings.

B: a group represented by A according to ~~claim 4~~ (1).

R⁴: a group represented by R¹ according to ~~claim 4~~ (1).

R⁵: a group represented by R² according to ~~claim 4~~ (1).

R⁶: a group represented by R³ according to ~~claim 4~~ (1),

provided that unsubstituted phenyl and indole which may be substituted are excluded.]

Page 14, lines 1-9:

(12) A pharmaceutical composition comprising the compound according to any of ~~claim 6 to 10~~ (6) to (10) as an active ingredient.

(13) The pharmaceutical composition according to ~~claim 14~~ (11), which is a platelet increasing agent.

(14) The pharmaceutical composition according to ~~claim 14~~ (11), which is a thrombocytopenia treating agent.

(15) The pharmaceutical composition according to ~~claim 11~~ (11), which is a c-Mpl ligand.

Page 63, line 13 to page 64, line 5:

30 μ l of triethylamine, 30 μ l of morpholine, 45 mg of WSC·HCl and 30 mg of HOBt were added to 2 ml of a THF solution of 52 mg of 1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-[[3-methoxypropyl](methyl)amino]methyl]thiazol-2-yl)carbamoyl]-2-pyridyl}piperidine-4-carboxylic acid hydrochloride, and the mixture was stirred overnight at room temperature. Chloroform was added to the reaction solution. The organic layer was washed with a saturated sodium hydrogencarbonate aqueous solution, with water and with brine, and then dried over sodium sulfate. After the solvent was distilled off, the residue was purified by silica gel column chromatography (eluent: chloroform:MeOH = 100:1 to 50:1, hexane:EtOAc = 2:1, then chloroform:MeOH = 20:1), and suspended in 2 ml of diethyl ether. 2 ml of ~~4N~~ 4M HCl-EtOAc was added, and the precipitate was collected by filtration to obtain 25 mg of 5-chloro-N-(4-(4-chlorothiophen-2-yl)-5-[[3-methoxypropyl](methyl)amino]methyl]thiazol-2-yl)-6-[4-(morpholinocarbonyl)piperidino]nicotinamide hydrochloride.